Alkermes, Inc.

Drug delivery technologies

Alkermes is a world leader in the development of products based on sophisticated drug delivery technologies.

Richard R. Pops, CEO
F. Ken Andrews, Chief Commercial Officer
Joseph J. Anisko, PhD, Vice President, Product Development and Leadership
David A. Broecker, President, COO
James M. Frates, Vice President, CFO, Treasurer

Michael A. Wall, Chairman
Floyd E. Bloom
Robert A Breyer
Gerri Henwood
Paul J. Mitchell
Richard F. Pops
Alexander Rich
Paul Schimmel
Mark Skaletsky

88 Sidney Street
Cambridge, Massachusetts 02139
USA
Phone: +1-617-494-0171
Fax: +1-617-494-9263

The focus of the company spans the development of controlled, sustained-release injectable drugs using ProLease® and Medisorb® technologies, as well as inhaled formulations based on their proprietary AIR® pulmonary technology. These particles can be delivered using small, simple inhalers, and can accommodate high drug doses and offer the potential for prolonged release. The first commercial product (Nutropin Depot) was developed in collaboration with Genentech, Inc. This is a recombinant human growth hormone formulated with ProLease technology.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.